The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?-Reference-Cited by-同舟云学术

The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?

Published:2020-06-05 Issue:5 Volume:191 Page:692-703
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Kazandjian Dickran¹^ORCID,Mo Clifton C.²^ORCID,Landgren Ola³^ORCID,Richardson Paul G.²^ORCID

Affiliation:

1. Multiple Myeloma Program Lymphoid Malignancies Branch Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda MD USA

2. Department of Medical Oncology Dana‐Farber Cancer Institute Jerome Lipper Multiple Myeloma Center Boston MA USA

3. Myeloma Service Department of Medicine Memorial Sloan Kettering Cancer Center New York City NY USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16764

Reference72 articles.

1. Cancer statistics, 2019

2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

3. Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

4. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

5. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

2. The Role of Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Multiple Myeloma: Is It Time to Rethink the Paradigm in the Era of Targeted Therapy?;Hemato;2024-04-09

3. Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis;Cytojournal;2024-03-18

4. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients;Bone Marrow Transplantation;2023-10-10

5. High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation;Frontiers in Oncology;2023-09-27